Zobrazeno 1 - 10
of 101
pro vyhledávání: '"O. E. DAHL"'
Publikováno v:
Acta Orthopaedica Scandinavica. 72:199-204
Low-molecular-weight heparin prophylaxis against thromboembolism aftertotal hip replacement--the never-ending story?
Autor:
O. E. Dahl
Publikováno v:
European Journal of Anaesthesiology. 17:343-347
Autor:
B. I . ERIKSSON, O. E. DAHL, N. ROSENCHER, A. A. KURTH, C. N. VAN DIJ K, S . P. FROSTICK, P. KALEBO, A. V. CHRISTIANSEN, S . HANTEL, R. HETTIARACHCHI, J . SCHNEE, H. R. BULLER, FOR THE RE-MODEL STUDY GROUP, BATTISTA BORGHI
Publikováno v:
Journal of thrombosis and haemostasis, 5(11), 2178-2185. Wiley-Blackwell
Summary. Background: Oral anticoagulants, such as dabigatran etexilate, an oral, direct thrombin inhibitor, that do not require monitoring or dose adjustment offer potential for prophylaxis against venous thromboembolism (VTE) after total knee replac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecff8aab35b764ee6cc072ef8dbee5b3
http://hdl.handle.net/11585/56816
http://hdl.handle.net/11585/56816
Publikováno v:
The Journal of bone and joint surgery. British volume. 90(2)
Thromboprophylaxis remains a controversial subject. A vast amount of epidemiological and trial data about venous thromboembolism has been published over the past 40 years. These data have been distilled and synthesised into guidelines designed to hel
Autor:
G, Agnelli, B I, Eriksson, A T, Cohen, D, Bergqvist, O E, Dahl, M R, Lassen, P, Mouret, N, Rosencher, M, Andersson, A, Bylock, E, Jensen, B, Boberg
Publikováno v:
Thrombosis research, 123(3), 488-497. Elsevier Limited
Background Ximelagatran, the first oral direct thrombin inhibitor, was shown to be an effective antithrombotic agent but was associated with potential liver toxicity after prolonged administration. Objectives and Methods The aim of the EXTEND study w
Autor:
O. E. Dahl, A. M. Pleil
Publikováno v:
Journal of thrombosis and haemostasis : JTH. 1(5)
Summary. Clinical guidelines recommend the use of extended out-of-hospital thromboprophylaxis in patients who have had major arthroplasty. However, the cost-effectiveness of prolonging pharmacological thromboprophylaxis into the out-of-hospital phase
Autor:
O E, Dahl
Publikováno v:
Thrombosis and haemostasis. 82(2)
Following certain major operative procedures, large amounts of tissue factor may be released from damaged tissues to venous blood. Mechanical and chemical injury to the collecting veins exposes subendothelial procoagulant proteins. This initiates a m
Autor:
O. E. Dahl
Publikováno v:
UPCommons. Portal del coneixement obert de la UPC
Universitat Politècnica de Catalunya (UPC)
Universitat Politècnica de Catalunya (UPC)
Autor:
G, Andreassen, O E, Dahl
Publikováno v:
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 117(14)
Hip replacement surgery is associated with a high frequency of postoperative deep vein thrombosis. This prospective study was performed in order to investigate if routine bedside questioning and examination by the visiting doctor could reveal deep ve
Autor:
O E, Dahl, G, Andreassen, T, Aspelin, C, Müller, P, Mathiesen, S, Nyhus, M, Abdelnoor, J H, Solhaug, H, Arnesen
Publikováno v:
Thrombosis and haemostasis. 77(1)
Discontinuation of thromboprophylaxis a few days after surgery may unmask delayed hypercoagulability and contribute to late formation of deep venous thrombosis (DVT). To investigate whether thromboprophylaxis should be prolonged beyond the hospital s